Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. (Nasdaq:TEVA) pertaining to pending Abbreviated New Drug Applications (ANDAs) for bioequivalent versions of Wellbutrin(R) generic wellbutrin sr sr and Zyban(R) (Bupropion Hydrochloride) 100 mg and 150 mg Extended Release Tablets filed by Andrx, as well as by Impax. Final approval also is dependent upon FDA's evaluation of generic wellbutrin sr any new information subsequent to the tentative approval. Food and Drug Administration. Close to 90% of Teva's sales are in North America generic wellbutrin sr and Europe. Thirteen of these filings were made under Paragraph IV of generic wellbutrin sr the Hatch-Waxman Amendments. The convertible debenture financing completed on April 5, 2004 provides us with additional financial resources going forward.

" Commenting on the Company's product pipeline, Larry Hsu, Ph. , IMPAX's President, said, "The launch of our generic Generic wellbutrin sr wellbutrin SR represents IMPAX's single largest product opportunity to date. Glaxo is Generic wellbutrin sr alleging infringement of patents on bupropion, the active ingredient in Wellbutrin, and on Zyban.

Business Editors/Health/Medical Writers LAURELTON, N. --(BUSINESS WIRE)--Nov. Net income for the 2004 first quarter was $9,048,000, Generic wellbutrin sr or $0. 14 per fully generic wellbutrin sr diluted share, compared with a net loss of $3,213,000, or $(0. 07) per share, in the prior year first quarter. Securities and Exchange Commission (SEC). (Nasdaq:ELAB) announced that on April 26, 2004, GlaxoSmithKline and Eon Labs generic wellbutrin sr filed in the U.
For press releases and other company information, generic wellbutrin sr visit the Eon Labs, Inc. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Fifteen of these filings were made under Paragraph IV of the Hatch-Waxman Amendments. This product is indicated for the treatment of depression. Eon generic wellbutrin sr labs Manufacturing, Inc.
Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, generic wellbutrin sr uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements.